The pharmaceutical industry, in recent years, has been marked by a cycle of outrage from patient groups, insurers and politicians each time a particularly expensive new drug hits the market. The considerable ticket price attached to blockbuster newcomers inevitably draws a widespread public outcry, and, lingering in the media spotlight, are often cited as the most likely culprits driving the skyrocketing drug costs in the United States.
Indeed, several high-profile drugs have entered the market with prohibitive prices that have undoubtedly driven up average costs of medications — perhaps
Uncategorized